Interest in modulating the immune response beyond glucocorticoids has existed since the COVID-19 pandemic began. Recent trials have shown promising results with IL-6 inhibitors such as tocilizumab although similar data on Sarilumab is lacking. In this report, we analyze the current evidence on Sarilumab in hospitalized COVID-19 patients to evaluate its efficacy.